STAT

FEBRUARY 14, 2024

Public health messages have told us for decades that if you smoke, you should quit. And if you don’t smoke, don’t start. But a new study suggests smoking may be even worse than we thought. The study , published Wednesday in Nature, underscores the importance of never lighting up that first cigarette, based on its conclusion that smoking has much longer harmful effects on immune responses than previously understood.

Immunization 363

Immunization Immunity 363

PharmaVoice

FEBRUARY 14, 2024

The pharma giant’s leader of a collective devoted to health equity discusses how companies can put their money where their mouth is to reach communities in need.

130

130

STAT

FEBRUARY 14, 2024

Last week, the Washington Post published an op-ed by former CDC Director Tom Frieden titled, “It’s the world’s leading killer. Make it the focus of the next breakthrough.” Frieden writes, “Hypertension, the ‘silent killer,’ is the deadliest but most neglected and widespread pandemic of our time, killing more than 10 million people a year worldwide.

335

335

The Pharmacist

FEBRUARY 14, 2024

The General Pharmaceutical Council (GPhC) has announced the appointment of five new members to its governing council, including a community pharmacist. Adeyemi (Ade) Williams, superintendent pharmacist and director of M J Williams Pharmacy, and lead pharmacist at the Bedminster Pharmacy, Bristol, will begin his term on 1 April 2024. Joining him will be Professor Dianne […] The post GPhC announces five new council members appeared first on The Pharmacist.

123

123

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

STAT

FEBRUARY 14, 2024

The Federal Trade Commission is launching a probe into the extent to which group purchasing organizations and wholesalers may contribute to ongoing shortages of key medicines at hospitals and other facilities across the country. The agency will explore how these companies — which are responsible for brokering and distributing countless medicines — might misuse their market power to influence pricing and availability.

Nursing Homes 346

Nursing Homes Hospitals Chemotherapy Drug Pricing 346

Pharma Times

FEBRUARY 14, 2024

The aggressive type of cancer accounts for 13% of all lung cancer cases worldwide

Communication 168

Communication 168

pharmaphorum

FEBRUARY 14, 2024

Discover how artificial intelligence (AI) is revolutionising the drug development process and transforming the way FDA-approved drugs are produced, ensuring compliance and optimising the supply chain. Learn more about the future of AI in pharmaceuticals.

Drug Development 129

Drug Development 129

STAT

FEBRUARY 14, 2024

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was  followed by  eight additional adalimumab biosimilar launches. These nine  FDA-approved  products offer lower-cost alternatives to the  world’s bestselling drug, Humira , used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders.

Biosimilars 343

Biosimilars 343

BioPharma Dive

FEBRUARY 14, 2024

Latigo Biotherapeutics has raised $135 million to develop drugs that block NaV1.8, a target shared by a Vertex therapy that just succeeded in Phase 3 testing.

126

126

STAT

FEBRUARY 14, 2024

After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals. The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

339

339

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

BioPharma Dive

FEBRUARY 14, 2024

The company and partner Biogen say signs from payers and doctors suggest the launch of Zurzuvae, the first oral therapy for PPD, is off to a good start.

126

126

STAT

FEBRUARY 14, 2024

A leaked version of a proposed agreement between India and the European Free Trade Association is causing alarm among civil society and patient advocacy groups over concerns the deal would delay access to affordable generic versions of newer, lifesavings medicines for several years. The language in a draft agreement, which is expected to be concluded by April, suggests changes would have to be made to India’s patent and regulatory laws.

343

343

European Pharmaceutical Review

FEBRUARY 14, 2024

Gilead Sciences has agreed to acquire CymaBay Therapeutics for a total equity value of $4.3 billion. Gilead confirmed that CymaBay’s lead product candidate seladelpar has a best-in-disease profile for second-line primary biliary cholangitis (PBC). This is based on data from the Phase III RESPONSE trial. The company shared that seladelpar is an oral, selective peroxisomeproliferator-activated receptor delta (PPARδ) agonist.

97

97

STAT

FEBRUARY 14, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hello! And it’s Meghana again. Today, we discuss how Biogen’s missed the mark with Leqembi, but how it’s also not exactly a surprise. We see a new startup emerge that aims to compete with Vertex Pharmaceuticals, and learn of Phase 1 results for Replicate’s srRNA rabies vaccine.

Vaccines 262

Vaccines Drug Pricing Drug Development 262

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

European Pharmaceutical Review

FEBRUARY 14, 2024

The development of drug products containing live anaerobic bacterial strains as the active pharmaceutical ingredient and where potency and shelf-life is typically associated with viable cell quantification, poses unique challenges when compared to both small and large molecule development therapeutics. It is the uniqueness of the strain and perceived inter-cellular variations (sub-populations) resulting from high viable cell densities during growth (fermentation) and the subsequent harvest and d

Dosage 97

Dosage Packaging Compounding Labelling 97

STAT

FEBRUARY 14, 2024

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.

Biosimilars 262

Biosimilars 262

European Pharmaceutical Review

FEBRUARY 14, 2024

A report by Allied Market Research predicts that the global pharmaceutical suspension market will reach $83.8 billion by 2032. Having valued $55.5 billion in 2022, the research expected that the market will reach a CAGR of 4.2 percent between 2023 and 2032. Factors driving the global pharmaceutical suspension market One of the main factors anticipated to propel the growth of the pharmaceutical suspension market is the availability of generic pharmaceutical suspensions, the research asserted.

95

95

STAT

FEBRUARY 14, 2024

WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts. Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection.

246

246

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

pharmaphorum

FEBRUARY 14, 2024

Ipsen has won FDA approval for first-line use of its pancreatic cancer therapy Onivyde, saying it is now part of a potential new “standard-of-care” for patients

105

105

Outsourcing Pharma

FEBRUARY 14, 2024

Stella Vnook, a seasoned veteran in the pharmaceutical industry with extensive experience in senior leadership roles at Catalent, Merck, and Diverse Biotech, has been a prominent figure in the field, particularly in oncology, for over 25 years.

91

91

Express Pharma

FEBRUARY 14, 2024

MSF has appealed to the Prime Minister to continue rightfully rejecting the inclusion of intellectual property provisions in the EFTA negotiations Following news that India and the European Free Trade Association (EFTA) – which comprises Iceland, Liechtenstein, Norway, and Switzerland – are close to finalising a trade deal, Doctors Without Borders/Médecins Sans Frontières (MSF), Public Eye, and Delhi Network of Positive People warned that if the final text retains the currently-included harmful

Generic Medicine 96

Generic Medicine Vaccines 96

Pharma Times

FEBRUARY 14, 2024

The report includes five recommendations for the government to address these issues

118

118

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

FEBRUARY 14, 2024

Eicos Sciences' Aurlumyn has become the first FDA-approved drug treatment to prevent amputations in cases of severe frostbite

110

110

The Guardian - Pharmaceutical Industry

FEBRUARY 14, 2024

Years of wrangling have ended in stalemate as campaigners question fairness of system for low and middle-income countries The World Trade Organization has failed to reach an agreement to waive intellectual property rights on Covid-19 tests and treatments for poorer countries. Members of the Trade-Related Aspects of Intellectual Property Rights (Trips) council said it could not reach consensus after years of discussion, despite the “considerable efforts” of members.

Vaccines 80

Vaccines 80

World Pharma News

FEBRUARY 14, 2024

A drug used to treat rheumatoid arthritis could also prevent the disease in individuals deemed to be at risk. Results from a Phase 2b clinical trial, published in The Lancet by researchers led by King's College London, provides hope for arthritis sufferers after it was shown that the biologic drug abatacept reduces progression to this agonising chronic inflammatory disease.

82

82

BioPharma Dive

FEBRUARY 14, 2024

The clearance of Onivyde for first-line pancreatic adenocarcinoma triggers a $225 million payment to Merrimack, from whom Ipsen bought the drug.

115

115

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Pharmaceutical Technology

FEBRUARY 14, 2024

A bipartisan group of lawmakers is seeking an investigation and sanctions against WuXi given alleged connections to the Chinese military.

78

78

Pharmafile

FEBRUARY 14, 2024

Ipsen has announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Onivyde (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (Nalirifox) as a first line treatment for adult patients with metastatic pancreatic adenocarcinoma (mPDAC). This approval is the second for an Onivyde regimen in mPDAC, following […] The post FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma treatment appeared first on

64

64

BioPharma Dive

FEBRUARY 14, 2024

The biotech is planning to dissolve less than four years after launching with plans to license drugs and market them in China and other Asian countries.

72

72

Drug Channels

FEBRUARY 14, 2024

It's Valentine’s Day—and commercial plan sponsors remain smitten with copay accumulators and maximizers. Our latest update finds that as of late 2023, about half of commercial lives were in plans that utilize a copay accumulator and/or a maximizer. These programs’ growth continues to divert the value of a manufacturer’s copay support payments away from patients and toward plans and PBMs.

89

89

Drug Patent Watch

FEBRUARY 14, 2024

This chart shows the drugs with the most patents in Ecuador. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Ecuador? appeared first on DrugPatentWatch - Make Better Decisions.

59

59